<DOC>
	<DOCNO>NCT02611895</DOCNO>
	<brief_summary>There theoretical possibility complete suppression HIV viral replication , subject use highly active association 25 antiretroviral drug currently available good treatment adherence . But key question remain : whether persist viral replication low noise HAART , since several argument suggest subclinical escape virus HAART least individual . The technique propose research consist detection quantification linear viral cDNA intra cytoplasmic , persistent novo infection marker order highlight subclinical replication active treatment HIV-1 consider optimize therapeutic management patient . Main objective : Comparing frequency patient infect HIV treat effectively ( HIV viral load undetectable plasma conventional method ) HIV DNA cytoplasm CD4 + T cell peripheral blood , cellular infection marker novo persistent , among patient therapeutic regimen contain viral integrase inhibitor raltegravir . Secondary objective - To evaluate frequency patient infect HIV treat effectively HIV DNA cytoplasm CD4 + T cell peripheral blood - Evaluate cause persistent infection de novo virological responder treatment ART : presence HIV genome encode strain resistant treatment ART ongoing noncompliance treatment , type antiretroviral therapy , CD4 nadir , pretreatment level plasma HIV RNA , total duration ART - Assess impact persistent novo infection virological responder : cell activation CD4 + CD8 + , lack immunological treatment response , change lymphocyte ratio T naïve / memory cell cell , presence transient increase viremia , residual viremia level - Identify virological responder may benefit treatment intensification</brief_summary>
	<brief_title>Testing Effect Raltegravir Persistent de Novo HIV Infection Virologic Responders Antiretroviral Therapy</brief_title>
	<detailed_description>There theoretical possibility complete suppression HIV viral replication , subject use highly active association 25 antiretroviral drug currently available good treatment adherence . But key question remain : whether persist viral replication low noise HAART , since several argument suggest subclinical escape virus HAART least individual . The technique propose research consist detection quantification linear viral cDNA intra cytoplasmic , persistent novo infection marker order highlight subclinical replication active treatment HIV-1 consider optimize therapeutic management patient . Main objective : Comparing frequency patient infect HIV treat effectively ( HIV viral load undetectable plasma conventional method ) HIV DNA cytoplasm CD4 + T cell peripheral blood , cellular infection marker novo persistent , among patient therapeutic regimen contain viral integrase inhibitor raltegravir . Secondary objective - To evaluate frequency patient infect HIV treat effectively HIV DNA cytoplasm CD4 + T cell peripheral blood - Evaluate cause persistent infection de novo virological responder treatment ART : presence HIV genome encode strain resistant treatment ART ongoing noncompliance treatment , type antiretroviral therapy , CD4 nadir , pretreatment level plasma HIV RNA , total duration ART - Assess impact persistent novo infection virological responder : cell activation CD4 + CD8 + , lack immunological treatment response , change lymphocyte ratio T naïve / memory cell cell , presence transient increase viremia , residual viremia level - Identify virological responder may benefit treatment intensification Methods : HIV patient recruit doctor Infectious Tropical Diseases Service ( MIT ) Montpellier University Hospital . As part research , three additional blood tube ( 7 ml EDTA tube ) collect , total 21 ml time blood sample carry two consultation schedule part usual care pathology HIV patient Service MIT . These consultation conduct baseline 3 6 month date inclusion .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Age &gt; = 18 year HIV1 infection Current number T CD4+ lymphocytes &gt; 200 cell / mm3 6 moth inclusion Efficient well tolerate antiretroviral treatment 12 month HIV1 viral load &lt; 50 copies/ml 12 month inclusion Patient able understand nature , objective method study Patient sign informed consent Affiliation French Social Security System Patient currently participate participate study ( within exclusion period define study ) Patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Aviremic HIV-1 infect patient</keyword>
	<keyword>HAART</keyword>
	<keyword>Integrase inhibitor Raltegravir</keyword>
	<keyword>Ongoing HIV infection</keyword>
</DOC>